This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FSDC vs. LGND, MIRM, BHC, SDGR, AAPG, BLTE, NAMS, JANX, SUPN, and ARWRShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Ligand Pharmaceuticals (LGND), Mirum Pharmaceuticals (MIRM), Bausch Health Companies (BHC), Schrödinger (SDGR), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), NewAmsterdam Pharma (NAMS), Janux Therapeutics (JANX), Supernus Pharmaceuticals (SUPN), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "medical" sector. FS Development vs. Ligand Pharmaceuticals Mirum Pharmaceuticals Bausch Health Companies Schrödinger Ascentage Pharma Group International Belite Bio NewAmsterdam Pharma Janux Therapeutics Supernus Pharmaceuticals Arrowhead Pharmaceuticals Ligand Pharmaceuticals (NASDAQ:LGND) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Do analysts prefer LGND or FSDC? Ligand Pharmaceuticals presently has a consensus target price of $146.43, suggesting a potential upside of 35.49%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Ligand Pharmaceuticals is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is LGND or FSDC more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to FS Development's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 4.95% beat FS Development's return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals29.68% 4.95% 4.39% FS Development N/A N/A N/A Does the media prefer LGND or FSDC? In the previous week, Ligand Pharmaceuticals had 9 more articles in the media than FS Development. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 0 mentions for FS Development. Ligand Pharmaceuticals' average media sentiment score of 1.05 beat FS Development's score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Ligand Pharmaceuticals Positive FS Development Neutral Which has stronger valuation & earnings, LGND or FSDC? Ligand Pharmaceuticals has higher revenue and earnings than FS Development. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M12.47$52.15M-$0.16-675.44FS DevelopmentN/AN/AN/AN/AN/A Do insiders and institutionals hold more shares of LGND or FSDC? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.8% of FS Development shares are owned by institutional investors. 5.9% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer LGND or FSDC? Ligand Pharmaceuticals received 553 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformLigand PharmaceuticalsOutperform Votes55370.45% Underperform Votes23229.55% FS DevelopmentN/AN/A SummaryLigand Pharmaceuticals beats FS Development on 12 of the 12 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$568.48M$6.70B$5.46B$7.72BDividend YieldN/A3.13%5.42%4.25%P/E RatioN/A7.2722.4418.49Price / SalesN/A239.68392.61101.64Price / CashN/A65.8538.1834.62Price / BookN/A6.306.674.19Net IncomeN/A$143.17M$3.22B$248.18M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$45.42-1.6%N/A+64.9%$568.48MN/A0.00N/ALGNDLigand Pharmaceuticals4.3828 of 5 stars$106.47+1.6%$146.43+37.5%+53.1%$2.05B$167.13M42.4280Positive NewsMIRMMirum Pharmaceuticals4.2235 of 5 stars$39.43+2.7%$58.20+47.6%+66.8%$1.95B$336.89M-19.52140BHCBausch Health Companies4.1917 of 5 stars$5.20+10.1%$7.17+38.0%-37.8%$1.91B$9.63B-43.2919,900Upcoming EarningsSDGRSchrödinger1.6863 of 5 stars$25.99-0.8%$33.00+27.0%+10.3%$1.90B$207.54M-11.11790Upcoming EarningsAAPGAscentage Pharma Group InternationalN/A$21.60+13.0%N/AN/A$1.88B$980.65M0.00600Gap UpBLTEBelite Bio2.9095 of 5 stars$58.38+6.7%$96.67+65.6%+46.5%$1.86BN/A-52.5910Positive NewsNAMSNewAmsterdam Pharma3.1473 of 5 stars$16.79+3.3%$43.33+158.1%-20.3%$1.84B$45.56M-6.464Positive NewsJANXJanux Therapeutics2.9895 of 5 stars$30.01+2.4%$95.25+217.4%-34.5%$1.77B$10.59M-25.6530News CoveragePositive NewsSUPNSupernus Pharmaceuticals3.1401 of 5 stars$30.84+1.8%$36.00+16.7%+7.1%$1.72B$661.82M28.82580Positive NewsARWRArrowhead Pharmaceuticals3.5816 of 5 stars$12.36+2.3%$41.44+235.3%-40.1%$1.70B$2.50M-2.39400Positive News Related Companies and Tools Related Companies Ligand Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Bausch Health Companies Competitors Schrödinger Competitors Ascentage Pharma Group International Competitors Belite Bio Competitors NewAmsterdam Pharma Competitors Janux Therapeutics Competitors Supernus Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
